News
Rapport Therapeutics, Inc. RAP-219 Phase 2a trial in patients with refractory focal epilepsy remains on track with topline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback